Pfizer (PFE) EBIAT (2009 - 2026)

Pfizer (PFE) has 18 years of EBIAT data on file, last reported at $2.7 billion in Q1 2026.

• EBIAT for Q1 2026 came in at $2.7 billion, down 8.7% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.5 billion (down 28.9% YoY), and the FY2025 annual result was $7.8 billion, down 3.04% from the prior year.
• EBIAT advanced to $2.7 billion in Q1 2026 per PFE's latest filing, from -$1.6 billion in the prior quarter.
• Over five years, EBIAT peaked at $9.9 billion in Q3 2022 and troughed at -$2.4 billion in Q4 2023.
• A 5-year average of $2.7 billion and a median of $2.8 billion in 2025 frame the typical range for EBIAT.
• The sharpest annual moves came in 2023 and 2025: EBIAT tumbled 127.55% in 2023, then soared 6997.56% in 2025.
• A 5-year view of EBIAT shows it stood at $225.0 million in 2022, then tumbled by 73.33% to $60.0 million in 2023, then jumped by 7341.67% to $4.5 billion in 2024, then plunged by 136.55% to -$1.6 billion in 2025, then surged by 265.99% to $2.7 billion in 2026.
• Business Quant data shows PFE's EBIAT at $2.7 billion in Q1 2026, -$1.6 billion in Q4 2025, and $3.6 billion in Q3 2025.